Abattis Bioceuticals Corp. (ATTBF) Subsidiary, Northern Vine, Provides Update on Growth Targets

“Northern Vine is ramping up for a busy finish to 2017,” said Northern Vine and Abattis President and CEO, Robert Abenante.

“We are very pleased with the progress of Northern Vine and are working hard to become a premiere cannabis laboratory and extraction processing center. Northern Vine is now poised for further growth and expansion. Given the progress of Northern Vine’s development, we anticipate that we will be ready for larger volume licensed producer (LP) clients by next quarter.”

Improved Capacity and Turn-Around Times

Northern Vine continues to successfully accept cannabis flower, oil and edible samples at its lab in Langley, BC. The team of scientists has improved their methods and procedures and are aiming to provide a full cannabinoid profile with the most efficient turnaround times in the market.

Additionally, Northern Vine has successfully submitted an application to Health Canada regarding enhancing its security from Level 3 to Level 6. Approval of this security level enhancement will increase the amount of controlled substances Northern Vine can hold and process in its lab to up to 25 kgs. This is expected to enable Northern Vine to exponentially increase the volume of services it can provide to LPs and ACMPR patients.

Arrival of Raybot Team

Northern Vine also welcomed the extraction team from Suzhou Raybot Material Tech Corp. (“Raybot”). Raybot’s contribution to Abattis’ and Northern Vine’s operations includes provision of Raybot’s proprietary extraction technology to Abattis and Northern Vine, and the granting of exclusive rights to sell and service Raybot’s extraction equipment. Delivery of two Raybot extraction machines is expected in the fall of 2017.

Strategically located in Langley, BC, Northern Vine is expected to be in the hub of major future testing and formulation activity. As Northern Vine streamlines its methods and customer service efforts, it plans to be a main service provider to the AMPCR market.

With the integration of Raybot’s technology and Northern Vine’s extraction and testing capabilities, Northern Vine is in the final stages of validating its various methods for a full array of services that include testing for potency, pesticides and heavy metals.

The arrival of the new machines will mark the beginning of the Company’s large-scale cannabinoid extraction business plan, which it hopes to replicate across Canada and globally.

New Additions to Northern Vine Lab Team

Northern Vine is pleased to announce the addition of scientists, Dr. Anika Singh and Akshita Puri, to its laboratory staff.

Dr. Singh holds a PhD in Food Science and Agricultural Chemistry from McGill University. Her projects have been funded by the Natural Sciences and Engineering Research Council of Canada (NSERC). She has composed several reviewed papers in various international journals of food science and nutrition.

Ms. Puri holds a Master’s degree in Biochemistry from McMaster University, with 7 years of research experience in the field of microbiology. Her experience includes managing multiple projects leading a team of 12 biotech professionals, and contributing to securing $2M in grant funding from the Canadian Institute of Health Research.

New Products

Science advisor, Dr. David Galvez, and the team at Northern Vine, are formulating a proprietary cannabinoid-infused product for strategic marketing and sales, with the goal of targeting Canadian, Australian, European and California markets. Product completion is anticipated for as early as fall 2017.

The team has identified an array of unique ingredients and delivery methods for maximum bioavailability and product efficacy and has begun brand development and marketing efforts around this initiative.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in, cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.